I am not a M.D. or a PHD. I simply have done some research into various immune cell relationships and non self antigens can cause DC responses that lead to improved migration. Intradermal injection places activated DCs in a lymph zone rich area. Lower dose reduces crowding not only of DCs interfering with DC migration but also from other responding immune cells like macrophages that kill unneeded or self antigen activated DCs which also contributes to crowding and leads to the death of non-self activated DCs because they can't get to a less crowded lymph zone interface before naturally coming to the end of their life cycle or being damaged from too much adverse signalling from what is happening around them. The lower doses helps prevent crowding and allows circulating T-cells to become activated in that local lymph zone. Recent research has shown that there are not only concentrated lymph zones throughout the body and tumor draining lymph zones but also lymph areas within at least some tumors as well. This is where DCVax-Direct can find an advantage.
News 
Market Data 
Discover 
